The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
 
Danka Zebic
No Relationships to Disclose
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew Martin
No Relationships to Disclose
 
Farzana Pashankar
Consulting or Advisory Role - Novartis
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Danish Mazhar
No Relationships to Disclose
 
Robert Huddart
Employment - Aspen Parkside Hopsital (I)
Leadership - Cancer clinic london Limited liability partnership
Consulting or Advisory Role - Bayer; Janssen Oncology; Merck Sharp & Dohme; Nektar; Roche
Speakers' Bureau - MSD; Roche
Research Funding - Astellas Pharma (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for dug discovery from Janssen (Inst)
Travel, Accommodations, Expenses - Nektar; Roche/Genentech
 
Matthew Wheater
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; MSD; Pfizer; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Healthcare at Home; Novartis
Research Funding - AVEO (Inst); GlaxoSmithKline/Novartis (Inst); GlaxoSmithKline/Novartis (Inst); MSD (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; Novartis
 
Euan Walpole
No Relationships to Disclose
 
Elaine Dunwoodie
No Relationships to Disclose
 
Darren Feldman
Consulting or Advisory Role - Cigna
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Seagen
Other Relationship - UpToDate
 
Alison Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Bristol-Myers-Squib; Janssen Oncology; Merck Serono; Pfizer; Roche; Sanofi
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer
Research Funding - Genzyme
 
Amanda Stevanovic
No Relationships to Disclose
 
David Wyld
Consulting or Advisory Role - Ipsen; Novartis; Novartis
Speakers' Bureau - Ipsen
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen; MSD Oncology; Novartis; Novartis; Novartis
 
Fritha Hanning
Employment - Canopy Healthcare Group
Leadership - Canopy Healthcare Group
Stock and Other Ownership Interests - Canopy Healthcare Group
 
Peter Grimison
Research Funding - ASLAN Pharmaceuticals (Inst); Boston Biomedical (Inst); Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Epizyme (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); QED Therapeutics (Inst); Specialised Therapeutics (Inst); Tilray (Inst)